Overview

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the relative bioavailability by measuring the extent and rate of absorption of different tablet formulations of AZD1656 in T2DM patients.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca